Ophthotech has completed patient enrolment in its Phase IIa clinical trial of Zimura (avacincaptad pegol) in combination with Lucentis (ranibizumab) for treating naïve patients with wet age-related macular degeneration (AMD).
AMD is a medical condition that could lead to blurred or no vision in the centre of the visual field.
The dose-ranging, multi-centre trial includes a total of 64 patients.
The trial aims to evaluate safety at different dosages and to identify a potential efficacy signal.
Data from the trial is expected to be evaluated at month six, while initial top-line data are scheduled to be provided before the end of this year.
Ophthotech chief medical officer Kourous Rezaei said: “Following the completion of this trial, clinical data will be analysed to assess whether to proceed to a randomised, sham controlled clinical trial of Zimura combination therapy in wet AMD.”
Zimura (avacincaptad pegol) was developed by Ophthotech as a complement factor C5 inhibitor for treating patients with wet AMD.
Apart from the Phase IIa, Zimura is currently being investigated as monotherapy in a Phase IIb clinical trial for patients with geographic atrophy secondary to dry AMD and in a Phase IIb clinical trial for the prevention of autosomal recessive Stargardt disease (STGD1).
Additionally, Zimura is being analysed as combination therapy with Eylea (aflibercept), an anti-VEGF agent, in patients with idiopathic polypoidal choroidal vasculopathy (IPCV).
Lucentis (ranibizumab) is an anti-vascular endothelial growth factor (anti-VEGF) agent.
